CDK16 knockdown also leads to a reduced expression of MYC and membrane programmed cell death‐ligand 1 (PD‐L1), two possible factors contributing to cancer cell senescence and immunotherapy effects, respectively [50, 51, 52]. The gene discussed is CDK16; the disease is cancer.